Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Total Current Liabilities: 2010-2025

Historic Total Current Liabilities for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to $9.4 million.

  • Lineage Cell Therapeutics' Total Current Liabilities fell 32.33% to $9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.4 million, marking a year-over-year decrease of 32.33%. This contributed to the annual value of $14.0 million for FY2024, which is 22.18% down from last year.
  • Lineage Cell Therapeutics' Total Current Liabilities amounted to $9.4 million in Q3 2025, which was down 12.77% from $10.8 million recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Total Current Liabilities ranged from a high of $47.1 million in Q4 2021 and a low of $6.6 million during Q1 2021.
  • Moreover, its 3-year median value for Total Current Liabilities was $15.3 million (2024), whereas its average is $14.6 million.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Total Current Liabilities skyrocketed by 506.46% in 2021, and later plummeted by 59.71% in 2022.
  • Over the past 5 years, Lineage Cell Therapeutics' Total Current Liabilities (Quarterly) stood at $47.1 million in 2021, then crashed by 59.71% to $19.0 million in 2022, then dropped by 5.38% to $18.0 million in 2023, then fell by 22.18% to $14.0 million in 2024, then plummeted by 32.33% to $9.4 million in 2025.
  • Its Total Current Liabilities was $9.4 million in Q3 2025, compared to $10.8 million in Q2 2025 and $13.1 million in Q1 2025.